2023
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Naqvi S, Riaz I, He H, Imran M, Orme J, Childs D, Ravi P, Hussain S, Singh P, Bryce A. The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. Journal Of Clinical Oncology 2023, 41: 5088-5088. DOI: 10.1200/jco.2023.41.16_suppl.5088.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerVolume of diseaseTriplet therapyDoublet therapyLV diseaseHazard ratioCastration-sensitive prostate cancerSensitive prostate cancerLow-volume diseaseEfficacious treatment optionConfidence intervalsInverse variance approachMixed treatment comparisonMCSPC patientsTreatment intensificationTreatment optionsClinical trialsProstate cancerEfficacious treatmentTreatment selectionDisease subgroupsPatientsComparative effectivenessTherapyDiseaseFirst-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Bin Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs D, Ravi P, Hussain S, Murad M, Boorjian S, Sweeney C, Van Allen E, Bryce A. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology 2023, 9: 635-645. PMID: 36862387, PMCID: PMC9982744, DOI: 10.1001/jamaoncol.2022.7762.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerAndrogen pathway inhibitorsSystemic treatment optionsProgression-free survivalOverall survivalTreatment optionsClinical trialsTriplet therapyProstate cancerFirst-line systemic treatment optionComparative effectivenessFirst-line treatment optionHigh-volume diseaseHigher adverse eventsImproved overall survivalLow-volume diseaseHealth-related qualityFuture clinical trialsDifferent treatment optionsHeterogeneous patient populationVolume of diseaseOutcomes of interestTriplet regimensEligible RCTs
2022
1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review
Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Khakwani K, Liu H, Hussain S, Singh P, Murad M, Bryce A. 1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. Annals Of Oncology 2022, 33: s1193. DOI: 10.1016/j.annonc.2022.07.1903.Peer-Reviewed Original Research